| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10485352 | Value in Health | 2005 | 9 Pages |
Abstract
Either DP/A or ASA appear to be a good value in comparison with no treatment, but there is no clear winner between the two. In the absence of a definitive randomized trial, simulation modeling can help clarify the trade-offs between the various antiplatelet agents, but not beyond the constraints imposed by the imprecision in the estimates that can be obtained from the current evidence base.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
David B. MD, Gregory P. PhD, Suping MS,